Relative Efficacy and Safety of Anti-Inflammatory Biologic Agents for Osteoarthritis: A Conventional and Network Meta-Analysis.
Yang LiYiying MaiPeihua CaoXin WenTianxiang FanXiaoshuai WangGuangfeng RuanSu'an TangChanghai DingZhaohua ZhuPublished in: Journal of clinical medicine (2022)
The findings suggest that infliximab may relieve pain more than other biological agents in OA patients. No significant differences were observed between biologics and placebo regarding physical function, stiffness, and risk of AEs. The results must be interpreted cautiously; therefore, further randomized controlled trials are warranted.
Keyphrases
- systematic review
- end stage renal disease
- rheumatoid arthritis
- anti inflammatory
- randomized controlled trial
- ejection fraction
- chronic kidney disease
- meta analyses
- newly diagnosed
- chronic pain
- knee osteoarthritis
- peritoneal dialysis
- prognostic factors
- pain management
- clinical trial
- patient reported outcomes
- open label